Lv4
560 积分 2024-09-16 加入
Obesity drugs aren’t always forever. What happens when you quit?
8小时前
已完结
FRI-383 Comparative anti-fibrotic action of resmetirom, semaglutide, tirzepatide and efruxifermin in the GAN diet-induced obese and biopsy-confirmed mouse model of MASH
1个月前
已关闭
FRI-370 Hepatoprotective effects of efruxifermin treatment in GAN diet-induced obese and biopsy-confirmed mouse model of MASH
1个月前
已关闭
88-OR: Long-Acting Amylin Analog AZD6234 in Combination with the GLP-1R Agonist Semaglutide Enhances Body Weight and Fat Mass Loss in Diet-Induced Obese (DIO) Rats
1个月前
已关闭
High levels of lipoprotein(a) in transgenic mice exacerbate atherosclerosis and promote vulnerable plaque features in a sex-specific manner
1个月前
已完结
Global epidemiology and implications of PNPLA3 I148M variant in MASLD: a systematic review and meta-analysis
2个月前
已关闭
682-P: Novel Dual Glucagon and Glucagon-Like Peptide-1 Receptor Agonist LY3305677 Improves Glucose Control, Reduces Body Weight, and Increases Energy Expenditure in Mice
3个月前
已关闭
FGF21 reverses MASH through coordinated actions on the CNS and liver
3个月前
已完结
Downregulation of microRNA-145a-5p promotes steatosis-to-NASH progression through upregulation of Nr4a2
4个月前
已完结
Identification and utility exploration of a highly potent and long-acting bullfrog GLP-1 analogue in GLP-1 and amylin combination therapy
4个月前
已完结
皖公网安备34019202002308
